[Preliminary study on the inhibition of hepatitis B viral expression in vitro via specific receptors mediated ribozyme transfer].
Comparing with liposome and transferrin receptors (Tf-R) mediated transfection, a plasmid harboring foreign gene with hepatic specificity could be transfected via asialoglycoprotein receptors (ASGP-R) mediated endocytosis. A recombination plasmid pCMV-Ripc harboring a hammerhead ribozyme which aim at the pregenome RNA of HBV ayw subtype at the 1796 site in the genome was delivered into HepG2 cells (HBV transient transfected system) and 2.2.15 cells (HBV permanent transfected system) via receptors mediated gene transfer methods. ELISA results showed that the inhibition of HBsAg and HBeAg expression is 55.29% and 68.73% respectively when pCMV-Ripc is co-transfected with pUC-2HBV in HepG2 cells via ASGP-R mediated DNA transfer method. The result indicated that pCMV-Ripc is efficient to inhibit the expression of HBV antigen and ASGF-R method is a safe, liver-targeted delivery system, therefore it is possible to develop an in vivo gene therapy strategy aiming to the treatment of hepatic infectious disease.